<!DOCTYPE html>
<html>
    <head>
        <title>§ 28-4553 Excessive pricing in sales of prescription drugs, a violation of law.</title>
        <meta http-equiv='content-type' content='text/html; charset=utf-8' />
        <link rel='stylesheet' media='screen' type='text/css' href='../css/base.css' />
    </head>
    <body>
        <header>
            <div class='right'>
                <a href='../'>home</a>,
                <a href='about.html'>about</a>
            </div>
            <h1>The DC Code: § 28-4553 Excessive pricing in sales of prescription drugs, a violation of law.</h1>
            <a href='../'>Index</a> &rarr; <a href='../28.html'>28 Commercial Instruments and Transactions. (Refs & Annos)</a>
        </header>
        
            
                <p>It shall be unlawful for any drug manufacturer or licensee thereof, excluding a point of sale retail seller, to sell or supply for sale or impose minimum resale requirements for a patented prescription drug that results in the prescription drug being sold in the District for an excessive price.</p>
            
        

        

        
        <h3>Historical and Statutory</h3>
        <p>Legislative History of Laws

For Law 16-37, see notes following <a href='./28-4551.html'>§ 28-4551</a>.

DC CODE <a href='./28-4553.html'>§ 28-4553</a>

Current through December 11, 2012</p>
        

        
        <h3>Credits</h3>
        <p>(Dec. 10, 2005, D.C. Law 16-37, § 2, 52 DCR 9061.)

GENERAL NOTES

This chapter has been held unconstitutional in the case of Pharmaceutical Research and Mfrs. of America v. District of Columbia, 2005, 406 F.Supp.2d 56, 78 U.S.P.Q.2d 1822, affirmed 496 F.3d 1362, 83 U.S.P.Q.2d 1639, rehearing and rehearing en banc denied 505 F.3d 1343, 85 U.S.P.Q.2d 1144.</p>
        
    </body>
</html>
